Infusystem Hld Stock Price, News & Analysis

InfuSystem Holdings (NYSE American: INFU), a leading national healthcare service provider, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, before market open. The company will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results.

InfuSystem operates under a two-platform model: Patient Services, which includes Oncology, Pain Management, and Wound Therapy businesses, providing clinic-to-home healthcare solutions; and Device Solutions, which supports the Patient Services platform through direct payer rentals, pump and consumable sales, and biomedical services. The company maintains Centers of Excellence across Michigan, Kansas, California, Massachusetts, Texas, and Ontario, Canada.

InfuSystem Holdings (NYSE American: INFU) announced a planned CEO transition, with current President and COO Carrie Lachance set to succeed Richard DiIorio as Chief Executive Officer effective May 19, 2025. DiIorio will remain available as an advisor to support the transition.

Lachance, who joined the company in 2010, has served in various leadership roles including Senior Vice President of Clinical and Customer Services and Territory Sales Manager. She has been President since 2021, COO since 2019, and a board member since 2021.

The company reaffirmed its full-year 2025 guidance, projecting revenue growth of 8-10% and an Adjusted EBITDA margin exceeding 18.8%, surpassing 2024's performance despite planned investments in business applications.

InfuSystem Holdings (NYSE: INFU) reported strong financial results for Q4 and full year 2024, achieving record net revenues of $134.9 million, up 7% year-over-year. The company's performance showed significant improvements across key metrics:

Patient Services revenue reached $80.4 million (+5%) while Device Solutions revenue hit $54.5 million (+11%). Notable achievements include:

• Record operating cash flow of $20.5 million (+82%)
• Adjusted EBITDA of $25.3 million (+13%)
• Net income of $2.3 million ($0.11 per diluted share)
• Gross margin improved to 52.2% (+2%)

For 2025, InfuSystem projects revenue growth of 8-10% with Adjusted EBITDA margins expected to exceed 2024's 18.8%, despite planned technology upgrade investments of approximately $2.5 million.

InfuSystem Holdings (NYSE American: INFU) announced it will release its preliminary fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before market opening. The company will host an investor conference call at 9:00 a.m. Eastern Time on the same day to discuss the results.

Interested parties can participate in the call by dialing (833) 366-1127 or (412) 902-6773, or listen via a live webcast available in the Investors section of the company's website. A replay will be accessible for 90 days on the company's website or by calling (877) 344-7529 or (412) 317-0088 with replay access code 9301008 through March 11, 2025.

InfuSystem is a national healthcare service provider operating under a two-platform model: Patient Services (offering last-mile solutions for clinic-to-home healthcare) and Device Solutions (supporting Patient Services with direct payer rentals, pump and consumable sales, and biomedical services).

Sidoti Events, has announced its December Small-Cap Conference schedule for December 4-5, 2024. The two-day virtual event features presentations from numerous publicly traded companies, including Charles River Associates (CRAI) scheduled for 10:45-11:15 EST on December 4th. The conference includes a mix of company presentations and one-on-one meetings with various small-cap companies across different sectors. The presentation schedule is subject to change, and attendees are directed to www.sidoti.com/events for the most current schedule and webinar links.

InfuSystem Holdings (NYSE American: INFU) announced its participation in the upcoming Sidoti Small Cap Virtual Investor Conference on December 4, 2024. The company's leadership team, including CEO Richard DiIorio, CFO Barry Steele, and President/COO Carrie Lachance, will present at 10:00 a.m. ET.

The presentation will be available via webcast on the company's investor relations website, with a replay option available post-event. Management will also host one-on-one meetings throughout the day. InfuSystem operates under two platforms: Patient Services (providing clinic-to-home healthcare solutions) and Device Solutions (supporting direct payer clients with rentals, sales, and biomedical services).

InfuSystem Holdings (NYSE American: INFU) has appointed Ronald Hundzinski as an independent director to its Board of Directors, effective November 12, 2024. Hundzinski, who will serve until the next Annual Shareholders meeting in May 2025, brings significant financial expertise and operational experience. He currently serves as Chairman of Gentherm's Board of Directors and previously held CFO positions at TI Fluid Systems, Tenneco Inc., and BorgWarner. The appointment strengthens InfuSystem's board oversight with his extensive accounting, finance, and operational expertise in healthcare services.

InfuSystem Holdings reported strong Q3 2024 financial results with record net revenues of $35.3 million, up 11% year-over-year. Net income increased 162% to $1.8 million ($0.08 per diluted share). Patient Services revenue grew 8% to $20.8 million, while Device Solutions revenue rose 15% to $14.5 million. The company's gross margin improved to 53.9%, up 5.0%. Adjusted EBITDA reached $7.9 million, increasing 27% with margin expansion to 22.3%. Operating cash flow surged 91% to $12.5 million. The company entered new strategic partnerships with Smith+Nephew for wound therapy and became exclusive distributor of Chemo Mouthpiece® through SI Healthcare Technologies joint venture.

InfuSystem Holdings (NYSE American: INFU) announced it will release its third quarter 2024 financial results on November 7, 2024, before market open. The company will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results. InfuSystem operates through two platforms: Patient Services, providing clinic-to-home healthcare solutions for complex medical equipment, and Device Solutions, supporting direct payer clients with rentals, sales, and biomedical services.